Day One

8:00 am Coffee & Registration

8:50 am Chair’s Opening Remarks

iPSC Manufacturing Innovation Leaders Fireside Chat

9:00 am iPSC Innovation Leaders Panel – Strategies to Develop Sustainable & Scalable Processes

• Allen Feng Founder & Chief Scientific Officer, HebeCell
• Peter Andersen Chief Scientific Officer & Co-Founder, Vita Therapeutics
• Craig Beasley Chief Technology Officer, BlueRock Therapeutics

9:30 am Optimizing Scalable Bioprocessing to Effectively Develop iPSC-based Therapies

• Hiroki Ozawa Associate Director, Regenerative Medicine, Ajinomoto

Exploring Cell Line Generation Techniques to Enhance Starting Material Quality & Improve Downstream Outcomes

10:00 am Utilizing Single-Cell Omic Data to Optimize Donor Selection & Improve Starting Material Quality – An Allogeneic Approach

• Ying He Director, Molecular & Cellular Genomics, Allogene Therapeutics

10:30 am Morning Break & Speed Networking

11:30 am Overcoming Variability in iPSC Clone Sources to Improve Consistency & Quality of Starting Materials

• Dhruv Sareem Executive Director & Assistant Professor - Biomanufacturing Center, Cedars-Sinai Biomanufacturing Center

12:00 pm Clinical Grade Homozygous HLA iPSCs for Cell Therapy

• Larry Luchsinger Vice President and Director of Research Operations, Comprehensive Cell Solutions

Overcoming Scalability Challenges to Increase Patient Reach in Cost-Effective Manners

12:10 pm Developing Bioreactor Processes to Support Transitions from 2D to 3D Media for iPSC-Derived Effector Cells

• Kelly O’Neill Senior Associate Engineer, Century Therapeutics

12:40 pm Lunch Refreshments

1:40 pm Talk by our Expertise Partner, Lonza

2:10 pm Moving Towards Feeder-Free iPS-Derived Cell Manufacturing in Scalable Single-Use-Bioreactor

• Allen Feng Founder & Chief Scientific Officer, HebeCell

2:40 pm Roundtable: Debating the Current Barriers to Scalability & the Novel Tools Required to Improve End Products

• Tomoko Iwata Principal Scientist, Takeda
• Calvin Chan Team Leader & Director - Allogeneic Cell Therapy, Process Platform Chemistry, Manufacturing & Controls, BMS

3:10 pm Developing Robust, Efficient and Flexible Allogeneic iPSC Manufacturing Processes using a Scalable and Versatile Vertical-Wheel Bioreactor Family

• Sunghoon Jung Senior Director, Bioprocess R&D, PBS Biotech

Harnessing Analytical Tools to Support the Development of More Robust iPSCs

3:40 pm Afternoon Break

4:10 pm Moving Toward Meaningful Characterization of iPSCs by Live Imaging to Accurately Monitor Cell Behavior

• Anthony Asmar Biologist, NIST

4:40 pm Evaluating the Genomic & Epigenomic Integrity of iPSC-Derived Therapeutics for the Safe Clinical Application

• Mamad Khazaei Chied Scientific Officer, Inteligex

5:10 pm Panel Discussion: Discussing Characterization Approaches for Assessing Quality of iPS Cell Lines

• Bruno Marques Head of Process Development, Century Therapeutics
• Anne Plant Fellow & Chief of Biomaterials & Biosystems, NIST
• Zhu Pirot Director - Platform Competitive Generic Therapy & Analytical Development, Bayer

5:45 pm Close of Conference Day 1